173 related articles for article (PubMed ID: 29842917)
21. Loss-of-function mutations in cathepsin C in two families with Papillon-Lefèvre syndrome are associated with deficiency of serine proteinases in PMNs.
de Haar SF; Jansen DC; Schoenmaker T; De Vree H; Everts V; Beertsen W
Hum Mutat; 2004 May; 23(5):524. PubMed ID: 15108292
[TBL] [Abstract][Full Text] [Related]
22. Processing of Neutrophil α-Defensins Does Not Rely on Serine Proteases In Vivo.
Glenthøj A; Nickles K; Cowland J; Borregaard N
PLoS One; 2015; 10(5):e0125483. PubMed ID: 25945506
[TBL] [Abstract][Full Text] [Related]
23. Dipeptidyl peptidase 1 inhibition as a potential therapeutic approach in neutrophil-mediated inflammatory disease.
Chalmers JD; Kettritz R; Korkmaz B
Front Immunol; 2023; 14():1239151. PubMed ID: 38162644
[TBL] [Abstract][Full Text] [Related]
24. Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.
Korkmaz B; Horwitz MS; Jenne DE; Gauthier F
Pharmacol Rev; 2010 Dec; 62(4):726-59. PubMed ID: 21079042
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological inhibition of the cysteine protease cathepsin C improves graft function after heart transplantation in rats.
Liu B; Korkmaz B; Kraft P; Mayer T; Sayour AA; Grundl MA; Domain R; Karck M; Szabó G; Korkmaz-Icöz S
J Transl Med; 2023 Nov; 21(1):799. PubMed ID: 37946197
[TBL] [Abstract][Full Text] [Related]
26. Identification and Optimization of Novel Cathepsin C Inhibitors Derived from EGFR Inhibitors.
Hou W; Sun H; Ma Y; Liu C; Zhang Z
J Med Chem; 2019 Jun; 62(12):5901-5919. PubMed ID: 31145622
[TBL] [Abstract][Full Text] [Related]
27. Leukocyte cathepsin C deficiency attenuates atherosclerotic lesion progression by selective tuning of innate and adaptive immune responses.
Herías V; Biessen EA; Beckers C; Delsing D; Liao M; Daemen MJ; Pham CC; Heeneman S
Arterioscler Thromb Vasc Biol; 2015 Jan; 35(1):79-86. PubMed ID: 25395616
[TBL] [Abstract][Full Text] [Related]
28. E-64c-Hydrazide Based Cathepsin C Inhibitors: Optimizing the Interactions with the S1'-S2' Area.
Tromsdorf N; Ullrich FTH; Rethmeier M; Sommerhoff CP; Schaschke N
ChemMedChem; 2023 Sep; 18(18):e202300218. PubMed ID: 37424408
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological inhibition of cathepsin C (CatC) as a potential approach for cancer therapeutics.
Abideen SA; Khan M; Al-Harbi AI; Ahmad S
J Biomol Struct Dyn; 2023; 41(18):8682-8689. PubMed ID: 36264138
[TBL] [Abstract][Full Text] [Related]
30. Premedication with a cathepsin C inhibitor alleviates early primary graft dysfunction in mouse recipients after lung transplantation.
Rehm SRT; Smirnova NF; Morrone C; Götzfried J; Feuchtinger A; Pedersen J; Korkmaz B; Yildirim AÖ; Jenne DE
Sci Rep; 2019 Jul; 9(1):9925. PubMed ID: 31289357
[TBL] [Abstract][Full Text] [Related]
31. Structure of human dipeptidyl peptidase I (cathepsin C): exclusion domain added to an endopeptidase framework creates the machine for activation of granular serine proteases.
Turk D; Janjić V; Stern I; Podobnik M; Lamba D; Dahl SW; Lauritzen C; Pedersen J; Turk V; Turk B
EMBO J; 2001 Dec; 20(23):6570-82. PubMed ID: 11726493
[TBL] [Abstract][Full Text] [Related]
32. Papillon-Lefèvre syndrome with homozygous nonsense mutation of cathepsin C gene presenting with late-onset periodontitis.
Ragunatha S; Ramesh M; Anupama P; Kapoor M; Bhat M
Pediatr Dermatol; 2015; 32(2):292-4. PubMed ID: 24894642
[TBL] [Abstract][Full Text] [Related]
33. A novel mutation in the cathepsin C gene in a Pakistani family with Papillon-Lefevre syndrome.
Kurban M; Cheng T; Wajid M; Kiuru M; Shimomura Y; Christiano AM
J Eur Acad Dermatol Venereol; 2010 Aug; 24(8):967-9. PubMed ID: 20236208
[TBL] [Abstract][Full Text] [Related]
34. Clinical, genetic, and biochemical findings in two siblings with Papillon-Lefèvre Syndrome.
Cagli NA; Hakki SS; Dursun R; Toy H; Gokalp A; Ryu OH; Hart PS; Hart TC
J Periodontol; 2005 Dec; 76(12):2322-9. PubMed ID: 16332247
[TBL] [Abstract][Full Text] [Related]
35. Design and evaluation of inhibitors for dipeptidyl peptidase I (Cathepsin C).
Kam CM; Götz MG; Koot G; McGuire M; Thiele D; Hudig D; Powers JC
Arch Biochem Biophys; 2004 Jul; 427(2):123-34. PubMed ID: 15196986
[TBL] [Abstract][Full Text] [Related]
36. Protein modeling of cathepsin C mutations found in Papillon-Lefèvre syndrome.
Moghaddasian M; Arab H; Dadkhah E; Boostani H; Babak AR; Abbaszadegan MR
Gene; 2014 Mar; 538(1):182-7. PubMed ID: 24374475
[TBL] [Abstract][Full Text] [Related]
37. Identification of cathepsin C mutations in ethnically diverse papillon-Lefèvre syndrome patients.
Hart PS; Zhang Y; Firatli E; Uygur C; Lotfazar M; Michalec MD; Marks JJ; Lu X; Coates BJ; Seow WK; Marshall R; Williams D; Reed JB; Wright JT; Hart TC
J Med Genet; 2000 Dec; 37(12):927-32. PubMed ID: 11106356
[TBL] [Abstract][Full Text] [Related]
38. Serine protease inhibitors to treat inflammation: a patent review (2011-2016).
Soualmia F; El Amri C
Expert Opin Ther Pat; 2018 Feb; 28(2):93-110. PubMed ID: 29171765
[TBL] [Abstract][Full Text] [Related]
39. Long-term change of disease behavior in Papillon-Lefèvre syndrome: seven years follow-up.
Wang X; Liu Y; Liu Y; Dong G; Kenney EB; Liu Q; Ma Z; Wang Q
Eur J Med Genet; 2015 Mar; 58(3):184-7. PubMed ID: 25497043
[TBL] [Abstract][Full Text] [Related]
40. Haim-Munk syndrome and Papillon-Lefèvre syndrome are allelic mutations in cathepsin C.
Hart TC; Hart PS; Michalec MD; Zhang Y; Firatli E; Van Dyke TE; Stabholz A; Zlotogorski A; Shapira L; Soskolne WA
J Med Genet; 2000 Feb; 37(2):88-94. PubMed ID: 10662807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
